On May 16, 2025, the FDA fully approved Novavax’s Nuvaxovid protein-based COVID-19 vaccine, previously available under Emergency Use Authorization since July 2022. The decision was delayed as new agency leadership under the current administration conducted a more thorough review of COVID vaccines.
Click Here for More Information